Request the Crizotinib Case Study
The discovery—and subsequent application—of genetic biomarkers has led to rapid advances in oncology research. Scientists can now link genes to disease states and prognosis, enabling them to develop targeted therapies and selection that will ultimately result in more effective treatments.
Our Compendia Bioscience™ translational bioinformatics services team provides you with powerful tools to support your efforts in preclinical to companion diagnostic development.
Request this case study that includes a genomic survey of thousands of tumor samples subjected to full exome sequencing, which reveals:
- The known EML4-ALK fusion may be viable for new indication or label extension opportunities
- Significant recurrent mutations in ALK and MET
- Additional potential uses for the drug in various cancers
A member of our clinical development team will send the Crizotinib Case Study to the email provided in this request form.